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A Novel Frameshift Mutation in the ITGB3 Gene
Leading to Glanzmann’s Thrombasthenia in a Saudi
Arabian Family
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Khushnooda Ramzan b, Sulman Basit a,*
a
b

Center for Genetics and Inherited Diseases, Taibah University Almadinah Almunawwarah, Medina, Saudi Arabia
Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Abstract
Glanzmann’s thrombasthenia (GT) is an autosomal recessive congenital bleeding disorder of platelet aggregation.
Mutations in ITGA2B and ITGB3 genes result in quantitative and/or qualitative abnormalities of the glycoprotein receptor complex IIb/IIIa (integrin aIIbb3), which in turn impairs platelet aggregation and lead to GT. In this study, whole
genome single nucleotide polymorphism (SNP) genotyping as well as whole exome sequencing was performed in a
large family segregating GT. Analysis of the genotypes localized the disease region to chromosome 17q21.2eq21.3.
Filtration of whole exome data and candidate variants prioritization identiﬁed a pathogenic variant in the ITGB3 gene.
The single nucleotide deletion variant (c.2113delC) in exon 13 of the ITGB3 gene is predicted to cause a frameshift and
absence of vital C-terminal domains including the transmembrane helix and the cytoplasmic domain. Clinical variability
of the bleeding phenotype in affected individuals with the same mutation suggests that other genetic and nongenetic
factors are responsible for determining GT features.
Keywords: Exome sequencing, Glanzmann’s thrombasthenia, Homozygosity mapping, ITGB3 gene, Pathogenic variant

1. Introduction

G

lanzmann’s thrombasthenia (GT) is a rare
autosomal recessive inherited bleeding disorder. It was ﬁrst reported by Edward Glanzmann in
1918 [1] and is characterized by lifelong mucosal
bleeding and, in severe cases, may require platelet
transfusions. The overall prevalence of GT is low in
the general population; however, the incidence of
GT is considerably high in certain inbred populations including Jews, South Indians, Jordanian
Arabs, Iranian, French Gypsies, Palestinian, and
Iraqi because of high consanguinity [2-8].
Integrin subunit beta 3 (encoded by ITGB3) and
integrin alpha IIb chain (encoded by ITGA2B) are
present as a heterodimer alpha-IIb/beta-3 complex
(aIIbb3) at the outer membrane of platelets. They
control a cascade of cellular events leading to

platelet aggregation, which in turn result in clotting
of blood from a bleeding blood vessel [9,10]. Pathogenic mutations in ITGB3 and ITGA2B cause
quantitative or qualitative deﬁciency of the glycoprotein receptor (aIIbb3), which in turn impairs
platelet aggregation and leads to GT symptoms [11].
The blood of affected individuals with GT shows the
absence of platelet aggregation in response to all
physiologic stimuli [12]. GT is genetically heterogeneous, and a large number of missense, nonsense,
indels, and splice site mutations in the genes ITGB3
and ITGA2B have been known to cause GT [13].
The mutation spectrum of GT is continuously
updated, and a list of mutations is available at
https://glanzmann.mcw.edu/ [5,14]. Identiﬁcation of
mutations in ITGB3 and ITGA2B and their functional
characterization has led to an improved understanding of the biosynthesis and structureefunction
relationships of the aIIbb3complex with GT [13,15].
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Detection of mutations underlying GT facilitates
prenatal genetic diagnosis and preimplantation genetic diagnosis for at-risk families.
We screened Saudi patients with bleeding disorders from different parts of the kingdom and reported a novel missense mutation in the RASGRP2
gene in a family segregating inherited platelet
function disorder-18 (IPD-18) [16]. Here, we report a
homozygous single nucleotide deletion mutation in
the coding part of the ITGB3 gene in a large sixgeneration Saudi family with multiple affected
members having GT.

2. Materials and methods
2.1. Study approval and family recruitment
Ethical approval of the study was granted by the
Ethical Review Committee (ERC) of the College of
Medicine, Taibah University (Medina, Saudi Arabia). A large six-generation Saudi family with nine
affected individuals was recruited for the study. In
brief, 3e5 ml of whole blood was collected in EDTAcontaining blood vacutainers after securing written,
informed consents from 10 family members
including both asymptomatic parents (V:9, V:10),
three affected siblings (VI:5, VI:6, VI:7), and three
unaffected individuals (V:8, VI:4, VI:8). Parents
granted permission in case of minors. A pedigree
tree was drawn based on the information provided
by the parents of the affected siblings (Fig. 1A).
2.2. Clinical description of patients
A formal clinical examination was done at the
Madinah Maternity and Children Hospital (Madinah, Saudi Arabia) by a consultant hematologist.
Complete blood count was performed for all available affected individuals. Prothrombin time (PT) and
partial thromboplastin time (PTT) were measured to
assess the coagulation proﬁle. Blood biochemistry
was also performed to determine the level of creatinine, urea, and potassium. Agonists including

adenosine-di-phosphate, epinephrine, collagen, and
arachidonic acid were used to assess the platelet
aggregation. Platelet surface antigens including
CD41, CD42a, CD42b, and CD61 were used to detect
the presence and absence of integrin aIIbb3 complex.
The bleeding intensity was scored using the International Society of Thrombosis and Hemostasis
Bleeding Assessment Tool (ISTH-BAT) [17].
2.3. DNA extraction and spectrophotometry
The Qiagen QIAquick DNA extraction kit (Qiagen, Hilden, Germany) was used to extract genomic
DNA from the whole blood using the manufacturer’s protocol. The quality of the extracted DNA
was evaluated using a Nanodrop spectrophotometer
(Maestrogen Inc, Hsinchu City, 30091, Taiwan)
whereas its integrity was resolved through 1%
agarose gel electrophoresis.
2.4. Homozygosity mapping
Illumina iScan (Illumina, Inc. 5200 Illumina Way,
San Diego, CA 92122, USA) platform using
HumanOmni 2.5 M BeadChip was used to perform
whole genome single nucleotide polymorphism
(SNP) genotyping. A starting material of 200 ng
genomic DNA was obtained from four affected
members (siblings) and three unaffected members
(including both parents and one sibling). Details of
the protocol used are the same as described elsewhere [18,19]. Shared regions of homozygosity were
mapped using HomozygosityMapper (http://
www.homozygositymapper.org/)
and
Illumina
Genome Studio software (Illumina, Inc. 5200 Illumina Way, San Diego, CA 92122, USA) [20,21].
2.5. Whole exome sequencing
To detect the underlying pathogenic mutation
causing GT in affected members of the family,
Agilent SureSelect version 6 Exome enrichment kit

Fig. 1. (A) Large sic generation pedigree of a family segregating autosomal recessive Glanzmann’s thrombasthenia. (B) Skin bruising on the arm and
leg of an affected individual from the family.
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(Agilent Technologies, Inc. 5301 Stevens Creek Blvd,
Santa Clara, CA 95051, USA) with 98.3% RefSeq
coverage; capturing 214,405 exons and splice sites,
was used for whole exome sequencing (WES) to
sequence the entire coding region. About 70 ng of
genomic DNA of affected members was taken as a
startup material for the library preparation and
enrichment. Details of the protocols used are the
same as described elsewhere [22-24].
2.6. Sanger validation for the variant identiﬁed
The genetic variant identiﬁed by WES was validated through Sanger sequencing using the ABI
3500 genetic analyzer (Applied Biosystems, 850
Lincoln Centre Drive, Foster City, CA 94404, USA)
platform. Primers ﬂanking the variant in the ITGB3
gene were designed using Primer3 software (http://
frodo.wi.mit.edu/primer3/). Procedural details were
the same as used elsewhere [25].
The variant was searched in the literature, GT
Database, ExAC Database (http://exac.broadinstitute.
org/), Ensembl Database (http://asia.ensembl.org),
and HGMD (http://www.hgmd.cf.ac.uk/ac/index.
php). The pathogenicity of the mutation identiﬁed
in the present study was deﬁned based on the ACMG
guidelines.

3. Results

Table 1. Laboratory investigation performed and the test values obtained
for patients in this study.
Laboratory investigations

Test

Values

Blood biochemistry

WBC count
Hemoglobin
MCV
MCH
Platelet count
Creatinine
Potassium

10 billion cells/L
84 g/L
55 fL
16.4 pg
557 billion cells/L
0.8 mg
6.7 mEq/L

Coagulation proﬁle

PT
PTT

12 s
24 s

Platelet surface markers

CD41
CD61
CD42a
CD42b

Negative
Negative
Positive
Positive

Hemoglobin electrophoresis Hemoglobin A1 97%
Hemoglobin A2 2.3%
Hemoglobin F <1%
Note. MCH ¼ mean corpuscular hemoglobin; MCV ¼ mean
corpuscular volume; PT ¼ prothrombin time; PTT ¼ partial
thromboplastin time; WBC ¼ white blood cells.

from 8 to 9. Following symptoms allowed us to
obtain the ISTH-BAT score of 8 to 9 (consultation in
bleeding from minor wounds, cutaneous and oral
cavity bleeding, as well as packing in case of tooth
extraction). Moreover, the patients were classiﬁed as
grade II GT based on the Modiﬁed World Health
Organization bleeding score.

3.1. Clinical evaluation of patients
Three available affected members of the family
(VI:5, VI:6, VI:7) were clinically evaluated. Physical
examination revealed skin bruising on the arm and
leg (Fig. 1B). Episodes of mild bleeding from mucous
membrane and gums were noted in all individuals.
Urea and creatinine levels were within the normal
range. Platelet counts and platelet morphology was
normal. Laboratory tests showed no platelet aggregation in response to all physiologic agonists and
show reduced or absent clot reaction.
Bleeding
time/PFA-100
(Platelet
Function
Analyzer; Dade Behring Inc., Marburg, Germany)
closure time was found prolonged in affected individuals. Affected individuals were found negative
for CD41 and CD61 surface antigens; however,
CD42a and CD42b antigens were found positive. PT
and PTT were also in normal range. Hemoglobin A1,
A2, and F were found normal using electrophoresis
(Table 1). Both parents and available healthy individuals did not show any disease symptoms.
ISTH-BAT was used to calculate the overall
bleeding score. The overall bleeding score for the
clinical symptoms of affected individuals ranged

3.2. Whole genome SNP genotyping identiﬁed a
shared LOH region on 17q21.2eq21.3
Genotypes obtained as a result of genome-wide
SNP genotyping were analyzed for the detection of
loss of heterozygosity (LOH) regions. AutoSNPa
(http://dna-leeds.co.uk/autosnpa/) identiﬁed a 7Mbp (40e47 Mbp) shared homozygous region on
chromosome 17q21.2eq21.3 (Fig. 2A). The unaffected individuals and both parents are heterozygous for SNPs in the region.
3.3. WES data analysis detected a pathogenic
mutation in the ITGB3 gene
Illumina NextSeq500 (Illumina, Inc. 5200 Illumina
Way, San Diego, CA 92122, USA) platform generated 98.3% coverage of 214,405 exons along with
splice sites via WES of the patient sample. The
generated data were ﬁltered and annotated using
different suitable ﬁlter options. However, in order to
identify the underlying genetic variant, the common
homozygous region revealed by whole genome SNP
genotyping array was particularly focused because
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Fig. 2. A single nucleotide polymorphism (SNP) genotype on chromosome 17 showing a loss of heterozygosity (LOH) region in affected individuals
(VI:5, VI:6, VI:7). (A) The region contains the ITGB3 gene. (B) Partial sequence chromatogram of an exon 13 of the ITGB3 gene. (a) The electropherogram of an affected individual. (b) A sequence of a carrier individual. (c) The electropherogram of a control individual of the family. The deletion
of C nucleotide is underlined.

of the autosomal recessive nature of the disease.
Resultantly, a homozygous mononucleotide deletion mutation (chr17, 45380183, c.2113delC) leading
to a frameshift in the amino acid sequence
(p.Leu705fs) was identiﬁed in exon 13 of the ITGB3
gene. Moreover, an unbiased and hypothesis-free
approach was also used to ﬁlter whole exome
variant data. However, we failed to ﬁnd any other
potential candidate genetic variant as an underlying
cause of GT in the patients.
3.4. Sanger sequencing validate the segregation of
the mutation in the family
The variant identiﬁed was validated through
Sanger sequencing using ABI 3500 genetic analyzer
(Applied Biosystems, 850 Lincoln Centre Drive,
Foster City, CA 94404, USA) platform by targeted

sequencing of the region ﬂanking the deletion
variant (c.2113delC) in exon 13 of the ITGB3 gene.
Moreover, all available individuals of the family
were sequenced for the variant using the Sanger
approach. Data analysis through BioEdit software
(https://bioedit.software.informer.com/7.2/)
conﬁrmed that the variant segregates in the family
in an autosomal recessive manner. The affected
members of the family are homozygous for the
variant, whereas unaffected members showed heterozygous or normal chromatogram (Fig. 3B).
According to the ACMG guidelines, the frameshift variant c.2113delC (p.Leu705fs) is classiﬁed as
“likely pathogenic.”

4. Discussion
of

GT is an autosomal recessive inherited disorder
platelet function. Both qualitative and

Fig. 3. (A) Schematic representation of the integrin beta 3 protein. (B) Predicted mutant protein with missing transmembrane and cytoplasmic domains. INB ¼ 38e461; extracellular tail ¼ 634e718; helical transmembrane ¼ 719e741; cytoplasmic domain ¼ 742e788.

HEMATOLOGY/ONCOLOGY AND STEM CELL THERAPY 2022;15:21e26

quantitative deﬁciencies of the integrin aIIbb3
(GpIIb/IIIa) cause GT. Integrin aIIbb3 is a heterodimeric molecular complex, and it acts as a main
platelet membrane receptor molecule for ﬁbrinogen
[26] and thus plays a pivotal role in mediating
platelet aggregation leading to the clotting of the
blood [5,14,15]. Platelets with defective integrin
aIIbb3 cannot form aggregates and thrombi at the
site of vascular injury and therefore, results in
bleeding diathesis [27].
In this study, we report a novel homozygous
mononucleotide deletion (NM_000212.2; c.2113delC)
in a large six-generation consanguineous Saudi
family (Fig. 1A) segregating GT in an autosomal
recessive manner. The deletion causes a frameshift
(p.Leu705fs) and is predicted to change all amino
acids downstream. Consequently, frameshift affects
three domains of the integrin beta protein including
the tail domain, the helical transmembrane domain,
as well as the cytoplasmic domain (Fig. 3B). The
cytoplasmic domain is involved in the phosphorylation of multiple tyrosines (at amino acid positions
773 and 785) and threonine residues (at amino acid
positions 767 and 779) in response to thrombininduced platelet aggregation. The predicted mutant
protein lacks these residues (Fig. 3B).
Integrin aIIbb3 are synthesized individually in the
megakaryocytes followed by the complex formation
in the endoplasmic reticulum. Incorrect folding or
failure to form this complex leads to rapid intracellular degradation [28]. Therefore, a genetic defect in
one subunit alone can cause deﬁcient membrane
expression of the entire integrin aIIbb3 complex. We
propose that our patients lack the aIIbb3 complex
because of frameshift mutation and predicted premature termination of the protein most probably by
nonsense mediated decay at the mRNA level. Patients who lack aIIbb3 complex may develop antiaIIbb3 (allo)antibodies when exposed to platelet
transfusions [29]. Therefore, comprehensive care is
required in the prevention and management of
alloimmunization in these GT patients [30].
The mononucleotide deletion (c.2113delC) identiﬁed in this study leads to a frameshift in the 13th of
the total 15 exons. It is unlikely that nonsensemediated decay would completely degrade the near
full-length mRNA. The classical model proposes
that NMD occurs when translation terminates >
50e55 nt upstream of the 30 -most exoneexon junction [31]. In our case, the variant is located 22 bp
upstream of the 30 end of the exoneexon junction
and causing a frameshift. Consequently, a physiologically relevant amount of C-terminally truncated
protein will be present in the cell. However, this
protein is predicted to fail in proper folding and
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assemble in a complex, which may lead to intracellular degradation.
In our study, a deletion mutation caused a premature truncated protein formation because of a
frameshift in protein structure, as a result of which
the integrin molecule (aIIbb3) lost its adhesive receptor activity. Similar ﬁndings were reported by
Wang and colleagues [32] in 1997 whereby truncation of a functional cytoplasmic domain of b3 led to
malfunctioning of (aIIbb3) complex, resulting in GT.
It is known that genetic defects in ITGA2B and
ITGB3 genes are the underlying cause of GT
[28,33,34]. Majority of GT patients were found to
have compound heterozygous mutations [35]. GT
phenotypeegenotype correlation has not yet been
fully elucidated. Interfamilial as well as intrafamilial
clinical variability has been extensively observed.
Even individuals from the same family with an
identical mutation may have different bleeding
severity [36]. In this study, the individuals with the
same deletion mutation (c.2113delC) have different
bleeding scores, suggesting that the bleeding
phenotype is determined by other genetic and
nongenetic factors.
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